That was based on the phase III LIBERTY-AFRS-AIMS trial findings from 62 adults and kids with allergic fungal rhinosinusitis ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study ...
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ...
Early-onset cancers are rising worldwide, and this Cell Perspective argues that cancer prevention must move beyond static ...
For the second time in a span of four months, Insmed’s Brinsupri has come up short in a mid-stage trial designed to expand ...
Find better and more soundless sleep with these nasal strips, air purifiers and other anti-snoring tools.
KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track de ...
Sanofi SA SNY on Tuesday reported Phase 2 data for its experimental therapy lunsekimig in chronic respiratory diseases, ...
Does mouth taping help with snoring? Learn what the research says, potential risks, and safer, proven treatments that can ...
Kymera Therapeutics (KYMR) stays a Strong Buy on KT-621 Phase 1b AD results, FDA Fast Track, and $1.6B cash runway—click to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results